NEW YORK, July 13, 2020 - Arsenal Capital Partners (“Arsenal”), a leading private equity firm that invests in specialty industrials and healthcare companies, today announced several significant human capital updates.
Pharma Value Demonstration, a portfolio company of Arsenal, reached an agreement with the board of Cello Health plc on the terms of a recommended cash offer for the entire issued, and to be issued, share capital of Cello.
The acquisition of Epolin Chemicals LLC, with its global leadership in near-infrared absorbing dyes and thermoplastic compounds, significantly expands Chroma Color Corporation’s product offerings in targeted growth markets. Epolin serves customers developing groundbreaking products in sensors, security inks, light filters, touch-screens, night vision products, and eyewear. Epolin will operate as an independent subsidiary of Chroma Color and continue to maintain and invest in its strong customer and supplier relationships.
Fralock, a leading engineering and manufacturing provider of specialty material solutions for technically challenging and mission critical applications, announced today that it has completed the acquisition of Career Technologies USA. Fralock is a portfolio company of Arsenal Capital Partners, a specialized private equity firm with strong expertise in the specialty materials industry.
Arsenal Capital Partners is a specialized private equity firm with a deep focus in two sectors, Specialty Industrials and Healthcare. Our philosophy is to partner with talented management teams, provide them with access to world-class operating resources and patient capital, and develop positive, open and constructive relationships that foster long-term value creation.